Your browser doesn't support javascript.
loading
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
Balar, A V; Castellano, D E; Grivas, P; Vaughn, D J; Powles, T; Vuky, J; Fradet, Y; Lee, J-L; Fong, L; Vogelzang, N J; Climent, M A; Necchi, A; Petrylak, D P; Plimack, E R; Xu, J Z; Imai, K; Moreno, B H; Bellmunt, J; de Wit, R; O'Donnell, P H.
Afiliação
  • Balar AV; Perlmutter Cancer Center, New York University Langone Health, New York, USA.
  • Castellano DE; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Grivas P; Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Center, Seattle.
  • Vaughn DJ; Division of Hematology/Oncology, Abramson Cancer Center, Penn Medicine, Philadelphia, USA.
  • Powles T; Department of Genitourinary Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Vuky J; Department of Medicine/Oncology, Oregon Health and Science University, Knight Cancer Institute, Portland, USA.
  • Fradet Y; Department of Surgery/Urology, CHU de Québec-Université Laval, Québec City, Canada.
  • Lee JL; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Fong L; Department of Medicine, University of California San Francisco, San Francisco.
  • Vogelzang NJ; Department of Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, USA.
  • Climent MA; Department of Medical Oncology, Fundación Instituto Valenciano de Oncología, València, Spain.
  • Necchi A; Department of Medical Oncology, Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy.
  • Petrylak DP; Department of Internal Medicine/Medical Oncology, Smilow Cancer Hospital, Yale New Haven Health, New Haven, USA.
  • Plimack ER; Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA.
  • Xu JZ; Department of Medical Oncology, Merck & Co., Inc., Rahway, USA.
  • Imai K; Department of Medical Oncology, Merck & Co., Inc., Rahway, USA.
  • Moreno BH; Department of Medical Oncology, Merck & Co., Inc., Rahway, USA.
  • Bellmunt J; Department of Hematology and Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, USA.
  • de Wit R; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: r.dewit@erasmusmc.nl.
  • O'Donnell PH; Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, USA. Electronic address: podonnel@medicine.bsd.uchicago.edu.
Ann Oncol ; 34(3): 289-299, 2023 03.
Article em En | MEDLINE | ID: mdl-36494006
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article